DelveInsight’s “Central Nervous System Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Central Nervous System Lymphoma, historical and forecasted epidemiology as well as the Central Nervous System Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Central Nervous System Lymphoma market report provides current treatment practices, emerging drugs, Central Nervous System Lymphoma market share of the individual therapies, current and forecasted Central Nervous System Lymphoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Central Nervous System Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Central Nervous System Lymphoma market.
Some of the key facts of the Central Nervous System Lymphoma Market Report:
- As per Frank Gaillard et al. (2022), the study reported that primary CNS lymphomas are mostly present as solitary, in 60─70% of the cases and as multiple lesions with a predilection for the periventricular white matter, although they can also arise in the cortex or deep grey matter in 30─40% of the cases.
- According to Mendez et al. (2018), primary CNSL most commonly occurred in the brain parenchyma (80%), followed by CNS not otherwise specified (13%), spine (4%), and the leptomeninges (3%); Within the brain parenchyma, the frontal lobes (19%) were most commonly affected.
Got queries? Click here to know more about the Central Nervous System Lymphoma Landscape
Central Nervous System Lymphoma Market Overview
Central nervous system lymphoma (CNSL) is a rare non-Hodgkin lymphoma, in which malignant cells from lymph tissue form in the brain, spinal cord, or even the eyes in some cases.
It is categorized into two types, primary CNSL, is a type of lymphoma confined to the areas of the nervous system; while secondary CNSL always forms in other parts of the body, later spreading to the nervous system. The symptoms of CNSL are varied and mostly depend on the anatomical location of the tumor, ranging from no potential symptoms when the tumor is located in the meninges, to vision changes when its located near the eyes, and coordination changes when the mass occurs near the portions of the brain that control motor functions.
The diagnosis and staging of CNSL typically occur consecutively, which is done by a series of physical, neurological, or eye exams; various imaging procedures like MRI, CT scan, and PET scan; biopsies and studies of cerebrospinal fluid; and lab tests like Complete Blood Count (CBC), Blood Chemistry, and HIV test. The treatment for CNSL, which is decided based on assessment of a variety of factors, is essentially made up of Radiation, Chemotherapy, Steroids, and Medications like methotrexate; in most cases, they are given in combination to improve the treatment outcome.
Central Nervous System Lymphoma Epidemiological Insight
- According to NORD (2019), Primary Central nervous system lymphoma constitutes 4% of all brain tumors, with an annual incidence of 5 per 1,000,000, for a total of approximately 1,500 new cases per year in the United States.
- As per Leukemia & Lymphoma Society (2018), in the US, CNSL tends to be more common in men than women, with a median age of diagnosis being 55, while the same for AIDS−infected patients is 35.
- A study by Morales–Martinez et al. (2021), found that the US has shown an increase in the PCNSL rate of 1.7% per year in people older than 65 years (with stable rates in other age groups) during the period 1992–2011
- According to Lv et al. (2022), the age-adjusted incidence rate of primary CNSL had a fivefold increase, from 0.1/100,000 in 1975 to 0.5/100,000 in 2017, a fivefold increase. A statistically significantly increased trend was observed in patients aged 70–79 years with an AAPC of 2.4% from 2000 to 2017.
- As per Frank Gaillard et al. (2022), the study reported that primary CNS lymphomas are mostly present as solitary, in 60─70% of the cases and as multiple lesions with a predilection for the periventricular white matter, although they can also arise in the cortex or deep grey matter in 30─40% of the cases
- According to Mendez et al. (2018), primary CNSL most commonly occurred in the brain parenchyma (80%), followed by CNS not otherwise specified (13%), spine (4%), and the leptomeninges (3%); Within the brain parenchyma, the frontal lobes (19%) were most commonly affected.
Central Nervous System Lymphoma Market Outlook
The current management options for Central Nervous System Lymphoma can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for Central Nervous System Lymphoma, whereas the symptomatic treatment involves administration of granulocyte-colony stimulating factor (G-CSF), exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists.
The major market players in the Central Nervous System Lymphoma therapeutic market are Amgen, Sandoz (Novartis), Pfizer, Takeda, and X4 Pharmaceuticals, among others.
The report’s Central Nervous System Lymphoma market outlook helps to better understand the historic, current and forecasted Central Nervous System Lymphoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
According to DelveInsight, the Central Nervous System Lymphoma market in 7MM is expected to grow steadily during the study period 2019–2032.
Learn more by requesting for sample @ Central Nervous System Lymphoma Market Landscape
Central Nervous System Lymphoma Key Companies
- Kazia Therapeutics
- Cellectar Biosciences
- Ono Pharmaceutical
- Nurix Therapeutics
- and many more
Central Nervous System Lymphoma Therapies
- Paxalisib
- Iopofosine I 131
- Tirabrutinib
- NC-5948
- and many more
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Central Nervous System Lymphoma
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Central Nervous System Lymphoma Emerging Therapies
- Central Nervous System Lymphoma Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Central Nervous System Lymphoma Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Central Nervous System Lymphoma Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/